Preclinical and preliminary clinical studies support their neuroprotective potential: for instance, in Alzheimer’s disease model animals, EGCG intervention significantly reduced cerebral Aβ plaque deposition and phosphorylated tau protein while improving cognitive function. Here, MAPT is linked to Alzheimer disease.